Drugs / TS-142
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT05819710 | May → Aug 2023 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05707897 | Feb → Mar 2023 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05624944 | Dec 2022 → Dec 2023 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04873323 | Jun → Sep 2021 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04814771 | Apr → May 2021 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04746105 | Feb → Oct 2021 | obstructive sleep apnea syndrome | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04696952 | Jan 2021 → Jan 2022 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04557163 | Oct → Nov 2020 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04464239 | Sep 2020 → Jan 2021 | — | Taisho Pharmaceutical R&D Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04169906 | Jul → Oct 2016 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04169893 | Oct 2015 → Feb 2016 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04469023 | Sep 2020 → Nov 2021 | insomnia | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04573725 | Jul 2017 → Feb 2019 | insomnia | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05461352 | Oct 2022 → Mar 2024 | insomnia | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05453136 | Aug 2022 → Dec 2023 | insomnia | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TS-142 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04169893 ↗ |
| Known as | vornorexant | “receptor antagonist vornorexant/TS-142 in healthy Japanese participants” PMID 37563858 ↗ Sep 2023 |
| Action | Inhibit | “dual orexin receptor antagonist” PMID 37563858 ↗ Sep 2023 |
| Modality | Small molecule | “Novel compound with potent antagonistic activity against orexin receptors may be new treatment option for patients with insomnia.” PMID 35296912 ↗ Mar 2022 |
| Route | Oral | “single oral doses” NCT04464239 ↗ |